Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of an experimental COVID-19 vaccine to the United States as governments buy up supplies in hopes of securing a candidate that works.
The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery” of the vaccine, the two companies based in Europe said in a statement. Sanofi will get the bulk of the funds.
Read More